「吉美瑞生」获3.5亿C轮融资，干细胞疗法已落地乐城「先行先试」｜早起看早期

Core Viewpoint - Regend Therapeutics Limited has completed a C round financing of 350 million RMB, with funds aimed at advancing clinical applications of stem/progenitor cell products [3][8]. Group 1: Company Overview - Regend Therapeutics, founded in 2015, focuses on regenerative medicine using progenitor cells for organ repair and enhancement [3][4]. - The company is led by founder Zuo Wei, a PhD in cell biology from Tsinghua University, and CEO Zhang Ting, a PhD in biology from Tsinghua University [3]. Group 2: Product Pipeline - The core pipeline includes REGEND001 (autologous lung progenitor cells) and REGEND003 (autologous kidney progenitor cells), both of which are in clinical stages targeting chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF), and chronic kidney disease (CKD) [4][6]. - REGEND001 aims to regenerate healthy alveoli to improve lung function, with significant improvements observed in clinical trials compared to control groups [6][7]. - REGEND003, targeting diabetic kidney disease (DKD), utilizes a non-invasive method to obtain kidney progenitor cells from urine, showing promising preclinical results [7]. Group 3: Clinical Trials and Milestones - REGEND001 is set to initiate Phase 3 clinical trials in China in 2026 for COPD and IPF, with ongoing discussions with regulatory authorities [6]. - The product has already been approved for clinical transformation in the Boao Lecheng International Medical Tourism Pilot Zone, with over 140 treatments completed since May [7]. Group 4: Investment and Strategic Plans - The completion of the C round financing will support clinical advancement, international strategy, commercialization, and talent acquisition [8]. - The company plans to establish at least two regional production centers across China to enhance production capacity for clinical products [8]. Group 5: Investor Perspectives - Investors view Regend Therapeutics as a leading innovator in the regenerative medicine sector, with significant clinical progress and a strong competitive advantage [8][9]. - The company’s advancements in progenitor cell technology and successful clinical trials for COPD and IPF have garnered positive investor sentiment [9].